{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T02:46:18Z","timestamp":1773715578597,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T00:00:00Z","timestamp":1629504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T00:00:00Z","timestamp":1629504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Head and Neck Pathol"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s12105-021-01376-8","type":"journal-article","created":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T19:02:29Z","timestamp":1629572549000},"page":"427-433","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Immunohistochemical Reactivity of Prostate-Specific Membrane Antigen in Salivary Gland Tumors"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2959-8002","authenticated-orcid":false,"given":"Haruto","family":"Nishida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiko","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kusaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Kadowaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Daa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,21]]},"reference":[{"key":"1376_CR1","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1186\/s12885-020-07192-7","volume":"20","author":"ML Donswijk","year":"2020","unstructured":"Donswijk ML, van Leeuwen PJ, Vegt E, Cheung Z, Heijmink SWTPJ, van der Poel HG, et al. Clinical impact of PSMA PET\/CT in primary prostate cancer compared to conventional nodal and distant staging: a retrospective single center study. BMC Cancer. 2020;20:723.","journal-title":"BMC Cancer"},{"key":"1376_CR2","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/jjco\/hyaa004","volume":"50","author":"U Tateishi","year":"2020","unstructured":"Tateishi U. Prostate-specific membrane antigen (PSMA)-ligand positron emission tomography and radioligand therapy (RLT) of prostate cancer. Jpn J Clin Oncol. 2020;50:349\u201356.","journal-title":"Jpn J Clin Oncol"},{"key":"1376_CR3","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.3390\/molecules25071743","volume":"25","author":"M Czerwi\u0144ska","year":"2020","unstructured":"Czerwi\u0144ska M, Bilewicz A, Kruszewski M, Wegierek-Ciuk A, Lankoff A. Targeted radionuclide therapy of prostate cancer-from basic research to clinical perspectives. Molecules. 2020;25:1743.","journal-title":"Molecules"},{"key":"1376_CR4","doi-asserted-by":"publisher","first-page":"345","DOI":"10.4132\/jptm.2016.06.14","volume":"50","author":"WJ Oh","year":"2016","unstructured":"Oh WJ, Chung AM, Kim JS, Han JH, Hong SH, Lee JY, et al. Differential immunohistochemical profiles for distinguishing prostate carcinoma and urothelial carcinoma. J Pathol Transl Med. 2016;50:345\u201354.","journal-title":"J Pathol Transl Med"},{"key":"1376_CR5","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.radonc.2020.09.034","volume":"154","author":"MH Valstar","year":"2021","unstructured":"Valstar MH, de Bakker BS, Steenbakkers RJHM, de Jong KH, Smit LA, Klein Nulent TJW, et al. The tubarial salivary glands: a potential new organ at risk for radiotherapy. Radiother Oncol. 2021;154:292\u20138.","journal-title":"Radiother Oncol"},{"key":"1376_CR6","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.radonc.2020.12.007","volume":"154","author":"J Iwanaga","year":"2021","unstructured":"Iwanaga J, Ibaragi S, Nakano K, Takeshita Y, Tubbs RS. No convincing evidence for the presence of tubarial salivary glands: a letter to the editor regarding \u201cThe tubarial salivary glands: a potential new organ at risk for radiotherapy.\u201d Radiother Oncol. 2021;154:321\u20132.","journal-title":"Radiother Oncol"},{"key":"1376_CR7","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1007\/s00259-017-3737-x","volume":"44","author":"TJW Klein Nulent","year":"2017","unstructured":"Klein Nulent TJW, van Es RJJ, Krijger GC, de Bree R, Willems SM, de Keizer B. Prostate-specific membrane antigen PET imaging and immunohistochemistry in adenoid cystic carcinoma- a preliminary analysis. Eur J Nucl Med Mol Imaging. 2017;44:1614\u201321.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1376_CR8","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1007\/s00259-018-3993-4","volume":"45","author":"D Malik","year":"2018","unstructured":"Malik D, Kumar R, Mittal BR, Singh H, Bhattacharya A, Sood A, et al. 68Ga-labelled PSMA (prostate specific membrane antigen) expression in signet-ring cell gastric carcinoma. Eur J Nucl Med Mol Imaging. 2018;45:1276\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1376_CR9","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/RLU.0000000000003081","volume":"45","author":"A Ar\u00e7ay","year":"2020","unstructured":"Ar\u00e7ay A, Eiber M, Langbein T. Incidental finding of colon carcinoma related to high uptake in 18F-PSMA-1007 PET. Clin Nucl Med. 2020;45:561\u20132.","journal-title":"Clin Nucl Med"},{"key":"1376_CR10","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/RLU.0000000000003400","volume":"46","author":"F Soeda","year":"2021","unstructured":"Soeda F, Watabe T, Kato H, Uemura M, Nonomura N. Duodenal adenocarcinoma mimicking metastasis of prostate cancer on 18F-prostate-specific membrane Antigen-1007 PET\/CT. Clin Nucl Med. 2021;46:49\u201351.","journal-title":"Clin Nucl Med"},{"key":"1376_CR11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3390\/diagnostics11010129","volume":"11","author":"S Sirtl","year":"2021","unstructured":"Sirtl S, Todica A, Ilhan H, Zorniak M, Bartenstein P, Mayerle J. Incidental finding of a PSMA-positive pancreatic cancer in a patient suffering from a metastasized PSMA-positive prostate cancer. Diagnostics (Basel). 2021;11:129.","journal-title":"Diagnostics (Basel)"},{"key":"1376_CR12","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1097\/RLU.0000000000002701","volume":"44","author":"S Kuyumcu","year":"2019","unstructured":"Kuyumcu S, Has-Simsek D, Iliaz R, Sanli Y, Buyukkaya F, Akyuz F, et al. Evidence of prostate-specific membrane antigen expression in hepatocellular carcinoma using 68Ga-PSMA PET\/CT. Clin Nucl Med. 2019;44:702\u20136.","journal-title":"Clin Nucl Med"},{"key":"1376_CR13","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s42000-019-00106-8","volume":"18","author":"F Bertagna","year":"2019","unstructured":"Bertagna F, Albano D, Giovanella L, Bonacina M, Durmo R, Giubbini R, et al. 68Ga-PSMA PET thyroid incidentalomas. Hormones (Athens). 2019;18:145\u20139.","journal-title":"Hormones (Athens)"},{"key":"1376_CR14","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1097\/RLU.0000000000002010","volume":"43","author":"S Arora","year":"2018","unstructured":"Arora S, Damle NA, Parida GK, Singhal A, Nalli H, Dattagupta S, et al. Recurrent medullary thyroid carcinoma on 68Ga-prostate-specific membrane antigen PET\/CT: Exploring new theranostic avenues. Clin Nucl Med. 2018;43:359\u201360.","journal-title":"Clin Nucl Med"},{"key":"1376_CR15","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s11307-018-01307-0","volume":"21","author":"T Ahn","year":"2019","unstructured":"Ahn T, Roberts MJ, Abduljabar A, Joshi A, Perera M, Rhee H, et al. A review of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) in renal cell carcinoma (RCC). Mol Imaging Biol. 2019;21:799\u2013807.","journal-title":"Mol Imaging Biol"},{"key":"1376_CR16","doi-asserted-by":"publisher","first-page":"527","DOI":"10.2967\/jnumed.119.234187","volume":"61","author":"J Kuten","year":"2020","unstructured":"Kuten J, Fahoum I, Savin Z, Shamni O, Gitstein G, Hershkovitz D, et al. Head-to-head comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET\/CT in staging prostate cancer using histopathology and immunohistochemical analysis as a reference standard. J Nucl Med. 2020;61:527\u201332.","journal-title":"J Nucl Med"},{"key":"1376_CR17","first-page":"247","volume":"8","author":"R Chakravarty","year":"2018","unstructured":"Chakravarty R, Siamof CM, Dash A, Cai W. Targeted \u03b1-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine. Am J Nucl Med Mol Imaging. 2018;8:247\u201367.","journal-title":"Am J Nucl Med Mol Imaging"}],"container-title":["Head and Neck Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12105-021-01376-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12105-021-01376-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12105-021-01376-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T16:45:58Z","timestamp":1654879558000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12105-021-01376-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,21]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1376"],"URL":"https:\/\/doi.org\/10.1007\/s12105-021-01376-8","relation":{},"ISSN":["1936-0568"],"issn-type":[{"value":"1936-0568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,21]]},"assertion":[{"value":"21 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study is approved by the institutional ethics committee (approval number: 2096).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The study is retrospective and the patriciate\u2019s consent is obtained through opt-out.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Approve.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}